The editorial discusses the recently approved Alzheimer's drug lecanemab, highlighting concerns about its modest benefits and uncertain long-term effects. While the drug showed some cognitive improvements in clinical trials, the author notes the benefits were small and the long-term impact remains unclear. The editorial suggests more research is needed to fully understand lecanemab's efficacy and safety profile.
Lecanemab’s benefits are too small and uncertain
Informational, non-clinical synthesis informed by published research. Not a clinical guideline or medical advice. May contain errors or editorial interpretation. Consult the original source and your physician.
